


# Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort

Manuel Francisco Ugarte-Gil <sup>1,2</sup>, Rocio Violeta Gamboa-Cardenas,<sup>1,2</sup> Cristina Reátegui-Sokolova <sup>1,3</sup>, Victor Román Pimentel-Quiroz <sup>1,2</sup>, Mariela Medina,<sup>1</sup> Claudia Elera-Fitzcarrald,<sup>1,2</sup> Francisco Zevallos,<sup>1</sup> Cesar Augusto Pastor-Asurza,<sup>1,4</sup> Federico Zazzetti,<sup>5</sup> Chetan S Karyekar,<sup>6</sup> Graciela S Alarcón,<sup>7,8</sup> Risto Alfredo Perich-Campos<sup>1,4</sup>

**To cite:** Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, *et al*. Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort. *Lupus Science & Medicine* 2022;9:e000641. doi:10.1136/lupus-2021-000641

▶ Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/lupus-2021-000641>).

Preliminary results were presented at the 2021 ACR Congress (<https://acrabstracts.org/abstract/severe-flares-are-associated-with-a-poorer-health-related-quality-of-life-hrqol-in-systemic-lupus-erythematosus-sle-patients/>).

Received 12 December 2021  
Accepted 17 March 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Manuel Francisco Ugarte-Gil; [mugarte@cientifica.edu.pe](mailto:mugarte@cientifica.edu.pe)

## ABSTRACT

**Background** Flares in patients with SLE, regardless of their severity, have been associated with damage accrual. However, their impact on health-related quality of life (HRQoL) has not been fully evaluated. In fact, disease activity is only minimally associated with HRQoL.

**Objective** To determine the association between flares and HRQoL.

**Methods** Patients from the Almenara Lupus Cohort were included. Visits occurring between December 2015 and February 2020 were evaluated. Flares were defined as an increase on the SLE Disease Activity Index 2000 (SLEDAI-2K) of at least 4 points; severe flares were those with a final SLEDAI-2K  $\geq 12$  and mild-moderate flares all the others. HRQoL was measured using the LupusQoL. Univariable and multivariable generalised estimating regression equations were performed, adjusting for possible confounders. Confounders were determined at one visit, whereas the outcome was determined on the subsequent visit; flares were determined based on the variation of the SLEDAI-2K between these visits.

**Results** Two hundred and seventy-seven patients were included; 256 (92.4%) were female, mean age at diagnosis was 36.0 (SD: 13.3) years and mean disease duration at baseline was 9.1 (SD: 7.1) years. Patients had mean of 4.8 (SD: 1.9) visits and a mean follow-up of 2.7 (1.1) years. Out of 1098 visits, 115 (10.5%) flares were defined, 17 were severe and 98 mild-moderate. After adjustment for possible confounders, only severe flares were associated with a poorer HRQoL in planning, pain, emotional health and fatigue.

**Conclusions** Severe flares, but not mild-moderate, flares are associated with poorer HRQoL.

## INTRODUCTION

The management of SLE has improved during the last several decades, improving patients' survival; however, these patients still have an impaired health-related quality of life (HRQoL).<sup>1</sup>

## Key messages

### What is already known about this subject?

- ▶ Flares have been associated with damage, but their impact on health-related quality of life (HRQoL) has not been fully evaluated.

### What does this study add?

- ▶ This study evaluates the impact of flares (mild-moderate or severe) on HRQoL.
- ▶ Severe flares are associated with poorer HRQoL.

### How might this impact on clinical practice or future developments?

- ▶ This study reinforces the need to develop effective strategies that allow us to prevent flares.

Several sociodemographic factors have been associated with an impaired HRQoL like age, ethnicity, poverty, lower educational level and inadequate social support.<sup>2-7</sup> The impact of disease activity<sup>2 8-11</sup> or damage<sup>12-14</sup> on HRQoL is still controversial. Flares have been associated with poorer HRQoL in France,<sup>15</sup> Thailand<sup>16</sup> and in the USA.<sup>17</sup> These studies did not differentiate flares based on their severity, and the US study was based on patient-reported flares. HRQoL is one of the indicators that should be measured in the monitoring of patients with SLE in routine clinical practice.<sup>18</sup>

Based on international consensus, flares are defined as: 'a measurable increase in disease activity in one or more organ systems involving new or worse clinical findings, laboratory measurements. It is a temporary event and must be considered clinically significant by the assessor and usually there would be at least consideration of a change or an increase in treatment'.<sup>19</sup> Flares have been associated

with a higher damage accrual,<sup>20–22</sup> higher direct and indirect cost.<sup>23 24</sup>

The aim of this study was to evaluate the impact of flares categorising them into mild-moderate and severe on HRQoL.

## METHODS

The Almenara Lupus Cohort has been previously described.<sup>25</sup> In short, this cohort was started in 2012 at the Rheumatology Department of the Hospital Guillermo Almenara Irigoyen in Lima, Peru. Patients included in the Almenara Lupus Cohort were managed by physicians from our Rheumatology Department who participated in the study. These visits took place in the ambulatory setting. Patients who signed the informed consent were recruited and followed every 6 months. Evaluations included an interview, medical records review, physical examination and laboratory tests. For these analyses, we have included those patients with at least two visits between December 2015 and February 2020.

SLE was defined using the 1997 revised American College of Rheumatology (ACR) criteria.<sup>26</sup> Demographic data included sex, age at diagnosis, socioeconomic status according to the Graffar method<sup>11</sup> and educational level, defined as years of formal education. Disease activity was ascertained using the SLE Disease Activity Index 2000 (SLEDAI-2K).<sup>27</sup> Damage was ascertained with the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI).<sup>28</sup> HRQoL was ascertained using the LupusQoL.<sup>29</sup> Therapeutic variables included current prednisone dose, antimalarials and immunosuppressive drug use (including methotrexate, azathioprine, leflunomide, mycophenolate mofetil, calcineurin inhibitors, cyclophosphamide and rituximab); the latter were recorded as current, past or never administered.

Flare was defined as an increase of the SLEDAI-2K of at least 4 points. Severe flares were those with a final SLEDAI-2K  $\geq 12$  and mild-moderate flares all the others.<sup>30 31</sup> Minimum clinically important differences (MCIDs) were defined using the cut-off proposed by McElhone *et al.*<sup>32</sup>

## Statistical analyses

Categorical variables are reported as numbers and percentages, numerical variables as mean and SD. The mean values for each LupusQoL domain at the index visit and at the subsequent visit as a function of the absence of flare or the presence of mild-moderate or severe flares were compared using analysis of variance.

Univariable and multivariable generalised estimating regression equations were performed for each domain of the LupusQoL, adjusting for possible confounders. Possible confounders included in the multivariable analyses were sex, age at diagnosis, socioeconomic status, educational level, disease duration, SDI, prednisone daily dose, antimalarial use, immunosuppressive drug use and the same domain of the LupusQoL. Confounders were

**Table 1** Characteristics of the patients at baseline

Characteristics	N (%) or mean (SD)
Female sex	256 (92.4)
Age at diagnosis, years	36.0 (13.3)
Disease duration, years	9.0 (7.0)
SLEDAI-2K	1.3 (2.5)
SDI $\geq 1$	164 (58.4)
SDI	1.3 (1.5)
Prednisone daily dose, mg/day	2.1 (3.4)
Antimalarial use	
Never	10 (3.6)
Past	19 (6.9)
Current	248 (89.5)
Immunosuppressive drug use	
Never	61 (22.0)
Past	68 (24.5)
Current	148 (53.4)
LupusQoL domain	
Physical health	66.1 (23.5)
Pain	68.0 (27.3)
Planning	68.6 (29.2)
Intimate relationship	59.1 (35.9)
Burden to others	53.3 (31.3)
Emotional health	64.5 (25.4)
Body image	60.0 (30.2)
Fatigue	61.8 (27.4)

N, number; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI-2K, SLE Disease Activity Index 2000.

determined at one visit, whereas the outcome was determined at the subsequent visit; flares were determined based on the variation of the SLEDAI-2K between these visits.

A  $p < 0.05$  was considered significant in all analyses. All analyses were performed using SPSS V.27.0 (IBM).

## RESULTS

Two hundred and seventy-seven patients were included; 256 (92.4%) were female, mean age at diagnosis was 36.0 (SD: 13.3) years and mean disease duration at baseline was 9.1 (SD: 7.1) years. Patients had mean of 4.8 (SD: 1.9) visits and a mean follow-up of 2.7 (1.1) years. Most patients in this cohort are Mestizo, that is of European and Amerindian ancestral background. General characteristics of these patients are depicted in [table 1](#). The most affected domains of the LupusQoL at baseline were burden to others, intimate relationship and body image.

The proportion of patients who achieved an MCID is depicted in [table 2](#).

**Table 2** Change in HRQoL between two consecutive visits

	Improved	Same	Worse
Physical health	285 (26.0%)	536 (48.8%)	277 (25.2%)
Pain	390 (35.5%)	337 (30.7%)	371 (33.8%)
Planning	370 (33.7%)	361 (32.9%)	367 (33.4%)
Intimate relationship	316 (28.8%)	448 (40.8%)	334 (30.4%)
Burden to others	298 (27.1%)	381 (34.7%)	419 (38.2%)
Emotional health	352 (32.1%)	424 (38.6%)	322 (29.3%)
Body image	349 (31.8%)	283 (25.8%)	466 (42.4%)
Fatigue	269 (24.5%)	394 (35.9%)	435 (39.6%)

HRQoL, health-related quality of life.

When we evaluated the HRQoL at the index visit, only emotional health was lower in those patients who will subsequently present severe flares. However, these patients had lower HRQoL in the pain, planning and emotional health domains at the subsequent visits. In contrast, patients with mild-moderate flares had similar values in all HRQoL domains than those without flares at the index visit (table 3).

Out of 1098 visits, 115 (10.5%) flares were defined, 17 were severe and 98 mild-moderate. The incidence of flares was 15.3 per 100 patient-years; this corresponded to 2.3 per 100 patient-years for severe flare and to 13.1 per 100 patient-years for mild-moderate flares. Univariable associations between variables and the domains of the LupusQoL are depicted in table 4. Of importance, severe

flares were associated with a poorer HRQoL in planning, pain, emotional health and fatigue. After adjustment for possible confounders, severe flares remained associated with a poorer HRQoL in the same domains (table 5).

## DISCUSSION

In this primarily Mestizo-prevalent lupus cohort, severe, but not mild-moderate, flares were associated with a lower HRQoL, independently of other well-known risk factors for this endpoint.

The mean HRQoL domain scores in our study were similar to those reported in other Latin America studies<sup>33–35</sup> including two from Peru which included the current cohort but also patients from other centres,<sup>36 37</sup>

**Table 3** LupusQoL domains before and after each visit as a function of the presence or absence of flares

	No flare	Mild-moderate flares	Severe flares	P value
	Mean (SD)	Mean (SD)	Mean (SD)	
<b>At the index visit</b>				
Physical health	68.0 (23.2)	64.1 (23.3)	63.5 (25.6)	0.192
Pain	70.7 (25.3)	67.3 (27.7)	58.3 (30.7)	0.058
Planning	71.0 (27.3)	70.0 (26.5)	65.3 (28.5)	0.638
Intimate relationship	59.4 (34.5)	53.1 (34.0)	68.8 (30.8)	0.265
Burden to others	55.1 (31.1)	55.5 (30.9)	55.6 (31.3)	0.990
Emotional health	65.8 (25.9)	66.4 (24.9)	50.8 (30.4)	0.032
Body image	61.6 (31.9)	62.0 (27.9)	54.7 (35.9)	0.691
Fatigue	63.2 (26.0)	64.6 (25.5)	54.2 (27.4)	0.287
<b>At the subsequent visit</b>				
Physical health	68.3 (23.0)	67.7 (22.4)	57.0 (25.5)	0.133
Pain	71.8 (24.5)	67.1 (27.6)	50.5 (30.7)	0.001
Planning	72.3 (26.1)	68.6 (27.4)	57.4 (28.5)	0.032
Intimate relationship	60.2 (34.1)	55.0 (33.7)	61.3 (37.5)	0.517
Burden to others	56.2 (31.1)	53.2 (31.4)	45.1 (36.1)	0.247
Emotional health	66.3 (25.8)	69.2 (25.7)	45.3 (27.0)	0.002
Body image	61.1 (32.2)	64.1 (31.1)	47.0 (30.9)	0.157
Fatigue	64.0 (25.5)	63.6 (25.7)	50.7 (25.9)	0.103

LupusQoL, Lupus Quality of Life.

**Table 4** Association between flares and health-related quality of life; univariable models

	Physical health		Pain		Planning		Intimate relationship		Burden to others		Emotional health		Body image		Fatigue	
	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value
<b>Flares</b>																
Severe	-11.3 (6.5)	0.084	-21.3 (7.7)	<b>0.006</b>	-14.9 (7.0)	<b>0.032</b>	1.0 (12.5)	0.939	-11.0 (8.4)	0.190	-20.9 (6.4)	<b>0.001</b>	-14.0 (7.8)	0.075	-13.3 (6.1)	<b>0.029</b>
Mild-moderate	-0.6 (2.3)	0.797	-4.7 (2.8)	0.095	-3.7 (2.9)	0.208	-5.3 (4.4)	0.232	-2.9 (3.3)	0.384	2.9 (2.7)	0.269	3.2 (3.3)	0.341	-0.4 (2.7)	0.876
No flares	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Male sex	6.8 (4.4)	0.124	6.7 (4.4)	0.130	3.5 (5.1)	0.489	12.1 (8.6)	0.157	0.4 (6.7)	0.951	2.5 (6.4)	0.703	3.2 (6.1)	0.604	3.6 (6.1)	0.549
Age at diagnosis, years	<b>-0.4 (0.1)</b>	<b>&lt;0.001</b>	<b>-0.4 (0.1)</b>	<b>&lt;0.001</b>	<b>-0.4 (0.1)</b>	<b>&lt;0.001</b>	<b>-0.9 (0.2)</b>	<b>&lt;0.001</b>	-0.1 (0.1)	0.303	<b>-0.3 (0.1)</b>	<b>0.002</b>	<b>-0.3 (0.1)</b>	<b>0.037</b>	<b>-0.3 (0.1)</b>	<b>0.013</b>
<b>Socioeconomic status</b>																
High	<b>11.7 (3.9)</b>	<b>0.003</b>	<b>11.0 (3.9)</b>	<b>0.005</b>	<b>12.0 (3.8)</b>	<b>0.002</b>	<b>19.5 (5.4)</b>	<b>&lt;0.001</b>	2.0 (4.8)	0.682	<b>10.0 (4.3)</b>	<b>0.019</b>	8.1 (4.4)	0.063	<b>8.3 (4.2)</b>	<b>0.047</b>
Medium	5.7 (3.9)	0.146	5.0 (4.0)	0.208	0.4 (4.1)	0.915	3.8 (5.9)	0.594	2.7 (5.0)	0.599	1.3 (4.5)	0.773	1.1 (4.6)	0.814	2.8 (4.1)	0.498
Low	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Educational level, years	<b>1.1 (0.5)</b>	<b>0.012</b>	<b>1.1 (0.5)</b>	<b>0.034</b>	<b>1.3 (0.4)</b>	<b>0.002</b>	<b>2.7 (0.7)</b>	<b>&lt;0.001</b>	0.2 (0.5)	0.603	<b>1.3 (0.5)</b>	<b>0.004</b>	<b>1.3 (0.5)</b>	<b>0.008</b>	<b>1.1 (0.5)</b>	<b>0.019</b>
Disease duration	0.1 (0.1)	0.561	0.2 (0.2)	0.232	<b>0.4 (0.2)</b>	<b>0.009</b>	0.4 (0.3)	0.164	<b>0.6 (0.2)</b>	<b>0.002</b>	<b>0.3 (0.2)</b>	<b>0.033</b>	0.2 (0.2)	0.417	<b>0.3 (0.2)</b>	<b>0.034</b>
SDI	<b>-3.9 (0.8)</b>	<b>&lt;0.001</b>	<b>-2.8 (0.9)</b>	<b>0.002</b>	-2.6 (0.9)	0.004	-2.4 (1.4)	0.082	-1.6 (1.0)	0.102	-0.9 (0.9)	0.315	<b>-2.1 (1.0)</b>	<b>0.036</b>	-1.1 (0.9)	0.197
Prednisone, mg/day	-0.5 (0.3)	0.138	-0.3 (0.3)	0.377	-0.6 (0.3)	0.088	0.7 (0.5)	0.181	-0.7 (0.4)	0.112	-0.3 (0.4)	0.355	0.2 (0.4)	0.568	-0.6 (0.4)	0.114
<b>Antimalarial use</b>																
Current	-5.9 (8.0)	0.464	-4.5 (7.4)	0.541	-11.3 (6.2)	0.070	-19.1 (10.9)	0.080	<b>-19.6 (6.3)</b>	<b>0.002</b>	-10.1 (7.5)	0.178	0.2 (13.7)	0.987	<b>-11.1 (4.9)</b>	<b>0.022</b>
Past	-5.9 (8.9)	0.509	-3.3 (8.4)	0.693	-6.2 (7.3)	0.391	-14.0 (12.2)	0.253	<b>-18.1 (7.8)</b>	<b>0.021</b>	-5.4 (8.6)	0.531	-1.0 (14.5)	0.947	-10.0 (6.3)	0.117
Never	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
<b>Immunosuppressive drug use</b>																
Current	-3.6 (3.1)	0.235	-4.9 (2.9)	0.093	-4.0 (3.6)	0.257	-4-6 (5.1)	0.372	-3.0 (4.5)	0.405	1.3 (3.4)	0.709	-0.6 (4.1)	0.878	2.0 (3.7)	0.598
Past	2.4 (3.3)	0.463	3.0 (3.3)	0.367	1.4 (4.0)	0.726	-1.5 (5.9)	0.801	-2.2 (5.0)	0.657	4.9 (3.9)	0.210	-0.4 (4.8)	0.936	<b>8.3 (4.1)</b>	<b>0.043</b>
Never	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Same domain of LupusQoL	0.7 (0.0)	<b>&lt;0.001</b>	<b>0.6 (0.0)</b>	<b>&lt;0.001</b>	<b>0.7 (0.0)</b>	<b>&lt;0.001</b>	<b>0.6 (0.0)</b>	<b>&lt;0.001</b>	<b>0.6 (0.0)</b>	<b>&lt;0.001</b>	<b>0.7 (0.0)</b>	<b>&lt;0.001</b>	<b>0.5 (0.0)</b>	<b>&lt;0.001</b>	<b>0.7 (0.0)</b>	<b>&lt;0.001</b>

Bolded entries are those with a p-value <0.05. LupusQoL, Lupus Quality of Life; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SE, SE of the estimate.

**Table 5** Association between flares and health-related quality of life. Multivariable models

	Physical health		Pain		Planning		Intimate relationship		Burden to others		Emotional health		Body image		Fatigue	
	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value	B (SE)	p value
<b>Flares</b>																
Severe	-7.4 (4.6)	0.105	-12.0 (5.1)	<b>0.020</b>	-10.1 (4.4)	<b>0.023</b>	-6.3 (10.1)	0.538	-10.9 (6.9)	0.116	-9.5 (4.3)	<b>0.028</b>	-10.4 (6.6)	0.113	-6.7 (2.9)	<b>0.023</b>
Mild-moderate	2.2 (1.7)	0.202	-1.9 (2.0)	0.343	-1.8 (1.8)	0.334	-2.6 (2.8)	0.357	-2.4 (2.6)	0.354	3.2 (1.8)	0.080	3.9 (2.7)	0.159	-0.3 (1.8)	0.868
No flares	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Male sex	<b>4.1 (2.0)</b>	<b>0.043</b>	<b>5.4 (2.3)</b>	<b>0.021</b>	<b>3.8 (2.4)</b>	0.106	<b>10.6 (4.6)</b>	<b>0.022</b>	<b>1.9 (3.1)</b>	0.543	<b>1.9 (2.5)</b>	0.435	<b>2.7 (3.6)</b>	0.448	<b>4.0 (2.3)</b>	0.076
Age at diagnosis, years	<b>-0.2 (0.0)</b>	<b>&lt;0.001</b>	<b>-0.1 (0.1)</b>	<b>0.005</b>	-0.1 (0.0)	0.068	<b>-0.4 (0.1)</b>	<b>&lt;0.001</b>	0.0 (0.1)	0.657	0.0 (0.0)	0.372	0.0 (0.1)	0.782	0.0 (0.0)	0.695
<b>Socioeconomic status</b>																
High	3.3 (2.0)	0.110	4.3 (2.4)	0.081	4.0 (2.2)	0.068	6.1 (4.4)	0.162	-1.5 (2.8)	0.576	1.5 (2.0)	0.443	1.1 (3.2)	0.728	-0.5 (2.2)	0.836
Medium	2.2 (1.7)	0.196	2.4 (2.1)	0.259	0.5 (1.8)	0.765	1.6 (3.7)	0.677	0.7 (2.3)	0.765	-0.1 (1.8)	0.942	-1.4 (2.9)	0.633	-0.5 (1.8)	0.763
Low	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Educational level, years	-0.1 (0.2)	0.647	-0.1 (0.3)	0.626	-0.1 (0.2)	0.787	0.0 (0.6)	0.936	0.2 (0.3)	0.556	0.2 (0.2)	0.409	0.6 (0.4)	0.097	0.4 (0.3)	0.185
Disease duration	-0.1 (0.1)	0.417	0.0 (0.1)	0.982	0.1 (0.1)	0.252	0.0 (0.1)	0.996	<b>0.3 (0.1)</b>	<b>0.015</b>	0.1 (0.1)	0.495	0.2 (0.1)	0.222	0.1 (0.1)	0.167
SDI	<b>-1.1 (0.4)</b>	<b>0.004</b>	<b>-1.0 (0.4)</b>	<b>0.016</b>	-0.8 (0.4)	0.050	-0.1 (0.8)	0.904	-0.8 (0.5)	0.084	-0.5 (0.4)	0.222	-1.1 (0.7)	0.087	-0.5 (0.4)	0.152
Prednisone, mg/day	-0.3 (0.2)	0.058	-0.1 (0.2)	0.676	-0.3 (0.2)	0.149	-0.4 (0.3)	0.191	-0.4 (0.2)	0.124	-0.3 (0.2)	0.153	0.0 (0.2)	0.872	<b>-0.3 (0.2)</b>	<b>0.034</b>
<b>Antimalarial use</b>																
Current	-1.4 (2.4)	0.559	1.2 (4.0)	0.761	-1.6 (2.4)	0.509	-6.0 (3.6)	0.090	<b>-6.7 (2.4)</b>	<b>0.009</b>	-2.1 (3.3)	0.528	4.7 (7.1)	0.507	-1.5 (2.1)	0.477
Past	-1.0 (2.8)	0.727	2.2 (4.3)	0.616	-0.1 (2.8)	0.960	-2.9 (5.1)	0.568	<b>-7.0 (3.1)</b>	<b>0.029</b>	0.1 (3.7)	0.981	2.1 (7.6)	0.785	-1.3 (2.6)	0.599
Never	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
<b>Immunosuppressive drug use</b>																
Current	-0.9 (1.2)	0.436	-1.6 (1.4)	0.161	-1.4 (1.5)	0.332	-1.3 (2.8)	0.648	-0.9 (2.0)	0.965	2.2 (1.4)	0.105	0.2 (2.5)	0.927	2.0 (1.4)	0.161
Past	0.9 (1.4)	0.519	0.6 (1.6)	0.709	0.5 (1.6)	0.763	-1.9 (3.4)	0.573	-1.5 (2.3)	0.508	2.6 (1.6)	0.096	1.0 (2.8)	0.712	<b>4.3 (1.6)</b>	<b>0.008</b>
Never	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Same domain of LupusQoL	<b>0.7 (0.0)</b>	<b>&lt;0.001</b>	<b>0.6 (0.0)</b>	<b>&lt;0.001</b>	<b>0.6 (0.0)</b>	<b>&lt;0.001</b>	<b>0.5 (0.0)</b>	<b>&lt;0.001</b>	<b>0.6 (0.0)</b>	<b>&lt;0.001</b>	<b>0.7 (0.0)</b>	<b>&lt;0.001</b>	<b>0.5 (0.0)</b>	<b>&lt;0.001</b>	<b>0.7 (0.0)</b>	<b>&lt;0.001</b>

Bolded entries are those with a p-value <0.05.  
LupusQoL, Lupus Quality of Life; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SE, SE of the estimate.



UK<sup>38</sup> and Canada<sup>39</sup>; overall these scores are higher than the original study from the USA<sup>40</sup> but not according with a more recent study from New York City.<sup>41</sup> These scores were lower than those reported from China.<sup>42</sup>

Our incidence of flares (15 per 100 patient-years) was slightly lower than the one reported in a study from Hong Kong (24 per 100 patient-years)<sup>23 43</sup> but similar to the one reported in China (12 per 100 patient-years),<sup>44</sup> Latin America (17 per 100 patient-years)<sup>20</sup> and in Padova, Italy (19 per 100 patient-years)<sup>45</sup> but higher than the one reported in Rome, Italy (7 per 100 patient-years).<sup>46</sup>

In a study from Hong Kong, investigators evaluated the cross-sectional association between flares in the preceding year and HRQoL, finding that those patients experiencing flares in the preceding year had a lower HRQoL in some domains (role limitation due to physical problems, general health, social function, role limitation due to emotional problems and the physical component summary (PCS) of the Short-Form 36 (SF-36)); however, in the multivariable model, the number of flares was only associated with role limitation due to physical problems. Severe flares were not associated with HRQoL.<sup>43</sup> In a study from Thailand, flares were associated with a lower PCS of the SF-36 and the global SLEQOL but not with the mental component summary of the SF-36.<sup>16</sup> In a post-hoc analysis of the BLISS 52 trial, patients who had flares had a worsening on their HRQoL in almost all the domains of the SF-36 (the only exception being role emotional).<sup>47</sup> In a study from France, authors examined the impact of flares (categorised based on the organ involved) and found that the physical domains of HRQoL were most affected by musculoskeletal and cutaneous flares, but also by renal and neurological flares; however, these authors did not take into account the severity of the flares.<sup>15</sup> In the Toronto cohort, using the same definition of flare, LupusQoL domain scores were lower in those who flared, but, they only had 14 visits (out of 376) defined as flare and they were not able to adjust the model for possible confounders.<sup>39</sup> However, in a study from the UK, worsening of disease activity [as measured using the British Lupus Isles Assessment Group (BILAG) index] was not associated with changes in the LupusQoL or the SF-36.<sup>32</sup>

Disease activity has been associated with HRQoL in previous reports,<sup>34 36 38 40 48 49</sup> but these studies evaluated this association cross-sectionally. A better control of disease activity, defined as the achievement of remission or low disease activity, has been associated with a better HRQoL in several cohorts<sup>16 50–55</sup> which is consistent with the data from our report.

When flares are reported by the patients, they tend to be associated with a poorer HRQoL as noted by Katz *et al* in a study from the USA<sup>17</sup>; furthermore, it is important to point out that patient-reported disease activity has been shown to be associated with worse HRQoL.<sup>56</sup>

Lower emotional health before the occurrence of severe flares could be a reflection of a more severe disease, but it could also reflect the presence of some manifestations otherwise not recognised in the physician-assessed

disease activity indices, but which are perceived by the patients. Further studies are needed to determine these associations.

Other variables associated with HRQoL in the multivariable models were male sex, age at diagnosis, disease duration, SDI, prednisone dose, antimalarial and immunosuppressive drug use. The association between male sex and age at diagnosis has been previously reported by other groups reinforcing the importance of socio-demographic factors on HRQoL.<sup>36 38 40</sup> The association between damage and treatment and HRQoL may reflect the impact of the severity of the disease on HRQoL which is consistent with has been reported by others.<sup>34 36 38 40 48 49</sup>

Our study has some limitations: first, as this is a prevalent cohort, we cannot exclude the impact of disease characteristics before the baseline visit. Second, due to the relatively small sample size, we were not able to evaluate the impact of specific types of flares on HRQoL. Third, due to the relatively low prevalence of some comorbidities, specifically of fibromyalgia and depression, we were not able to evaluate their impact on the patients' HRQoL. The main strength of this study is to evaluate the impact of flares (and its severity) in a primarily Mestizo Latin American population.

In conclusion, severe flares, but not mild-moderate, flares are associated with poorer HRQoL, mainly on planning, pain, emotional health and fatigue domains.

#### Author affiliations

<sup>1</sup>Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru

<sup>2</sup>Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru

<sup>3</sup>Unidad de Investigación Para La Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru

<sup>4</sup>Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Peru

<sup>5</sup>Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina

<sup>6</sup>Janssen R&D, Spring House, Pennsylvania, USA

<sup>7</sup>Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA

<sup>8</sup>School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru

**Twitter** Manuel Francisco Ugarte-Gil @mugartegil and Victor Román Pimentel-Quiroz @VictorioPQ

**Contributors** All authors were involved in drafting or revising this article critically for important intellectual content, and all authors approved the final version to be published. MFU-G has full access to all of the data from the study and takes responsibility for their integrity and the accuracy of the analyses performed. MFU-G is the guarantor.

**Funding** These analyses were done as a part of a research grant from Janssen. Additionally, the Almenara Lupus Cohort has been partially supported by institutional grants from EsSalud (1483-GCGP-ESSALUD-2013, 1733-GCGP-ESSALUD-2014 and the 2015 Kaelin Prize 04-IETSI-ESALUD-2016), from the Pan American League of Associations for Rheumatology (PANLAR) (2015 PANLAR Prize and the 2018 H Ralph Schumacher MD/JCR/PANLAR Prize) and from the Fundación Instituto Hipólito Unanue.

**Competing interests** MFU-G has grant support from Janssen and Pfizer. RVG-C has grant support from Pfizer. CR-S and VRP-Q have grant support from Janssen. FZ and CSK are employees of Janssen Scientific Affairs. All other authors declare to have no other conflicts of interest.

**Patient and public involvement** The Almenara Lupus Cohort used focus groups, interviews and questionnaires to determine the patients' priorities and preferences including which outcomes are relevant to them, and if there are any problems with the instruments used or the length of the visits. Patients are involved in recruitment

for the study, as they inform their relatives and friends about the cohort, and invite them to participate in the educational activities; if these contacts have SLE, they are invited into the cohort if they are affiliated with the Peruvian social security system. The results of our studies are reported to our patients during our different educational activities.

**Patient consent for publication** Not required.

**Ethics approval** This study involves human participants and has been approved by the Hospital Guillermo Almenara Irgoyen Institutional Review Board (3474-OCID-G-RAA-ESSALUD-11, 271-CEI-CIDG-RAA-ESSALUD-13, 302-CEI-ICD-G-RAA-14, 3027-OCID-G-RAA-ESSALUD-15 and 4072-OCID-G-HNGAI-ESSALUD-2017). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Manuel Francisco Ugarte-Gil <http://orcid.org/0000-0003-1728-1999>  
Cristina Reátegui-Sokolova <http://orcid.org/0000-0003-3421-2717>  
Victor Román Pimentel-Quiroz <http://orcid.org/0000-0002-3638-7054>

## REFERENCES

- Elera-Fitzcarrald C, Fuentes A, González LA, *et al*. Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. *Expert Rev Clin Immunol* 2018;14:915–31.
- Alarcón GS, McGwin G, Uribe A, *et al*. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. predictors of self-reported health-related quality of life early in the disease course. *Arthritis Rheum* 2004;51:465–74.
- Kulczycka L, Sysa-Jedrzejowska A, Robak E. Quality of life and satisfaction with life in SLE patients—the importance of clinical manifestations. *Clin Rheumatol* 2010;29:991–7.
- Kulczycka L, Sysa-Jedrzejowska A, Zalewska-Janowska A, *et al*. Quality of life and socioeconomic factors in Polish patients with systemic lupus erythematosus. *J Eur Acad Dermatol Venereol* 2008;22:1218–26.
- Golder V, Kandane-Rathnayake R, Hoi AY-B, *et al*. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. *Arthritis Res Ther* 2017;19:62.
- Kuriya B, Gladman DD, Ibañez D, *et al*. Quality of life over time in patients with systemic lupus erythematosus. *Arthritis Rheum* 2008;59:181–5.
- Franklyn K, Lau CS, Navarra SV, *et al*. Definition and initial validation of a lupus low disease activity state (LLDAS). *Ann Rheum Dis* 2016;75:1615–21.
- Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. *Clin Rheumatol* 2007;26:24–9.
- Kiani AN, Strand V, Fang H, *et al*. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. *Rheumatology* 2013;52:1651–7.
- Saba J, Quinet RJ, Davis WE, *et al*. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). *Joint Bone Spine* 2003;70:348–51.
- Tamayo T, Fischer-Betz R, Beer S, *et al*. Factors influencing the health related quality of life in patients with systemic lupus erythematosus: long-term results (2001–2005) of patients in the German Lupus Erythematosus Self-Help Organization (LULA Study). *Lupus* 2010;19:1606–13.
- Gladman DD, Urowitz MB, Gough J, *et al*. Fibromyalgia is a major contributor to quality of life in lupus. *J Rheumatol* 1997;24:2145–8.
- Stoll T, Gordon C, Seifert B, *et al*. Consistency and validity of patient administered assessment of quality of life by the mos SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. *J Rheumatol* 1997;24:1608–14.
- Legge A, Doucette S, Hanly JG. Predictors of organ damage progression and effect on health-related quality of life in systemic lupus erythematosus. *J Rheumatol* 2016;43:1050–6.
- Corneloup M, Maurier F, Wahl D, *et al*. Disease-Specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French equal cohort. *Rheumatology* 2020;59:1398–406.
- Louthrenoo W, Kasitanon N, Morand E, *et al*. Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study. *Arthritis Res Ther* 2020;22:8.
- Katz P, Wan GJ, Daly P, *et al*. Patient-Reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus. *Qual Life Res* 2020;29:3251–61.
- Mosca M, Tani C, Aringer M, *et al*. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. *Autoimmun Rev* 2011;10:383–8.
- Ruperto N, Hanrahan LM, Alarcón GS, *et al*. International consensus for a definition of disease flare in lupus. *Lupus* 2011;20:453–62.
- Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, *et al*. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. *Ann Rheum Dis* 2015;74:1019–23.
- Conti F, Ceccarelli F, Perricone C, *et al*. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. *Lupus* 2016;25:719–26.
- Stoll T, Sutcliffe N, Mach J, *et al*. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus—a 5-yr prospective study. *Rheumatology* 2004;43:1039–44.
- Zhu TY, Tam L-S, Lee VW-Y, *et al*. The impact of flare on disease costs of patients with systemic lupus erythematosus. *Arthritis Rheum* 2009;61:1159–67.
- Bertsias G, Karampli E, Sidiropoulos P, *et al*. Clinical and financial burden of active lupus in Greece: a nationwide study. *Lupus* 2016;25:1385–94.
- Ugarte-Gil MF, Gamboa-Cárdenas RV, Zevallos F, *et al*. High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients. *Lupus* 2014;23:969–74.
- Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.
- Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002;29:288–91.
- Gladman D, Ginzler E, Goldsmith C, *et al*. The development and initial validation of the systemic lupus international collaborating Clinics/American College of rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum* 1996;39:363–9.
- McElhone K, Abbott J, Shelmerdine J, *et al*. Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. *Arthritis Rheum* 2007;57:972–9.
- Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, *et al*. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. *Ann Rheum Dis* 2015;74:1019–23.
- Buyon JP, Petri MA, Kim MY, *et al*. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med* 2005;142:953–62.
- McElhone K, Abbott J, Sutton C, *et al*. Sensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosus. *Arthritis Care Res* 2016;68:1505–13.
- Machado Escobar MA, Yacuzzi MS, Martínez RN, *et al*. Validation of an Argentine version of lupus quality of life questionnaire. *Lupus* 2016;25:1615–22.
- Etcheagaray-Morales I, Méndez-Martínez S, Jiménez-Hernández C, *et al*. Factors associated with health-related quality of life in Mexican lupus patients using the LupusQoL. *PLoS One* 2017;12:e0170209.
- Carrión-Nessi FS, Marcano-Rojas MV, Romero Arocha SR, *et al*. Impact of demographic, clinical, and treatment compliance

- characteristics on quality of life of Venezuelan patients with systemic lupus erythematosus. *BMC Rheumatol* 2022;6:2.
- 36 Elera-Fitzcarrald C, Alva M, Gamboa-Cardenas R, *et al.* Factors associated with health-related quality of life in Peruvian patients with systemic lupus erythematosus. *Lupus* 2018;27:913–9.
- 37 Perea-Seoane L, Agapito-Vera E, Gamboa-Cardenas RV, *et al.* Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients. *Lupus* 2022;31:110–5.
- 38 McElhone K, Castelino M, Abbott J, *et al.* The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. *J Rheumatol* 2010;37:2273–9.
- 39 Touma Z, Gladman DD, Ibañez D, *et al.* Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? *J Rheumatol* 2011;38:1898–905.
- 40 Jolly M, Pickard SA, Mikolaitis RA, *et al.* LupusQoL-US benchmarks for us patients with systemic lupus erythematosus. *J Rheumatol* 2010;37:1828–33.
- 41 Kasturi S, Szymonifka J, Burket JC, *et al.* Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematosus. *J Rheumatol* 2017;44:1024–31.
- 42 Lai N-S, Lu M-C, Chang H-H, *et al.* A comparison of the correlation of systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) and systemic lupus erythematosus disease activity score (SLE-DAS) with health-related quality of life. *J Clin Med* 2021;10. doi:10.3390/jcm10102137. [Epub ahead of print: 15 05 2021].
- 43 Zhu TY, Tam L-S, Lee WY, *et al.* Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. *J Rheumatol* 2010;37:568–73.
- 44 Peng L, Wang Z, Li M, *et al.* Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. *Clin Rheumatol* 2017;36:2727–32.
- 45 Zen M, Bassi N, Nalotto L, *et al.* Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. *Clin Exp Rheumatol* 2012;30:856–63.
- 46 Conti F, Ceccarelli F, Perricone C, *et al.* Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. *PLoS One* 2012;7:e45934.
- 47 Jolly M, Annapureddy N, Arnaud L, *et al.* Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 trial. *Lupus* 2019;28:1628–39.
- 48 Wang S-li, Wu B, Leng L, *et al.* Validity of LupusQoL-China for the assessment of health related quality of life in Chinese patients with systemic lupus erythematosus. *PLoS One* 2013;8:e63795.
- 49 Shi Y, Li M, Liu L, *et al.* Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: a systemic review and meta-analysis. *Autoimmun Rev* 2021;20:102691.
- 50 Ugarte-Gil MF, Gamboa-Cárdenas RV, Reátegui-Sokolova C, *et al.* Better health-related quality of life in systemic lupus erythematosus predicted by low disease activity State/Remission: data from the Peruvian Almenara lupus cohort. *Arthritis Care Res* 2020;72:1159–62.
- 51 Ugarte-Gil MF, Pons-Estel GJ, Vila LM, *et al.* Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. *RMD Open* 2019;5:e000955.
- 52 Margiotta DPE, Fasano S, Basta F, *et al.* The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus. *Lupus* 2019;28:1705–11.
- 53 Goswami RP, Chatterjee R, Ghosh P, *et al.* Quality of life among female patients with systemic lupus erythematosus in remission. *Rheumatol Int* 2019;39:1351–8.
- 54 Poomsalood N, Narongroeknawin P, Chaiamnuay S, *et al.* Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus. *Lupus* 2019;28:1189–96.
- 55 Mok CC, Ho LY, Tse SM, *et al.* Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. *Ann Rheum Dis* 2017;76:1420–5.
- 56 Elera-Fitzcarrald C, Vega K, Gamboa-Cárdenas RV, *et al.* Discrepant perception of lupus disease activity: a comparison between patients' and physicians' disease activity scores. *J Clin Rheumatol* 2020;26:S165–9.